Bioactivity:

CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3_/_, CK2, Plk1 and SAPK2A. Phase 1.

CAS nr:

693228-63-6

Purity:

98%

Molecular Weight:

368,46

SMILES:

CC1=C(SC(N)=N1)C1=NC(NC2=CC=C(C=C2)N2CCOCC2)=NC=C1

Formula:

C18H20N6OS

Pathway:

Angiogenesis,Tyrosine Kinase/Adaptors,Tyrosine Kinase/Adaptors,Angiogenesis,Chromatin/Epigenetic,Cell Cycle/Checkpoint,MAPK,PI3K/Akt/mTOR signaling,Cell Cycle/Checkpoint

Target:

FLT,FLT,VEGFR,VEGFR,Aurora Kinase,Aurora Kinase,S6 Kinase,S6 Kinase,CDK